Meeting
2021 Gastrointestinal Cancers Symposium
A new radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemoradiation in locally advanced or unresectable rectal cancer: The dose-finding part of a phase I/II trial.
Authors
Jaw-Yuan Wang
Division of Colorectal Surgery, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
Jaw-Yuan Wang , Ching-Wen Huang , Ming-Yii Huang , Huang-Ming Hu , Wen-Hung Hsu , Hsiang-Yao Shih , Chiao-Yun Chen , Chou-Pin Chen , Jeffrey Yung-Chuan Chao , You-Hsin Chiu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02465593
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 66)
DOI
10.1200/JCO.2021.39.3_suppl.66
Abstract #
66
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1b/2 study of a radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemo-radiation in locally advanced or unresectable rectal cancer.
First Author: Ching-Wen Huang
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Tumor volume regression of rectal cancer in daily MRI during preoperative chemoradiotherapy with capecitabine.
First Author: Yoo-Kang Kwak
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang
Poster
2022 ASCO Annual Meeting
PKUCH 04 trial: Total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for pMMR/MSS locally advanced middle to low rectal cancer.
First Author: Aiwen WU